ArticleClinical, cosmetic and investigational dermatology2020
A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States.
Article in Clinical, cosmetic and investigational dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis.American journal of clinical dermatology · 2023Pooled it
- Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.American journal of clinical dermatology · 2026Trial
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.American journal of clinical dermatology · 2026Trial
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.The Journal of dermatology · 2026Trial
- Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme.Dermatology and therapy · 2026Article
- Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study.Dermatology and therapy · 2026Article
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey.Dermatology and therapy · 2026Article
- Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross-Sectional Survey Study.The Australasian journal of dermatology · 2026Article
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis.Dermatology and therapy · 2026Article
- Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan.The Journal of dermatology · 2026Article
- Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity in Adults in Taiwan: A Cross-sectional Survey.Dermatology and therapy · 2026Article
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata.Journal of health economics and outcomes research · 2026Article
- Perceived Stigma and Mental Health Disorders Among Adults With Alopecia Areata Living in Japan.The Journal of dermatology · 2025Article
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata.Dermatology and therapy · 2025Article
- Alopecia areata in solid organ transplant recipients: A retrospective analysis.JAAD international · 2025Article
- Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata.Dermatology and therapy · 2025Article
- Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Investigating the Genetic Association of Selected Candidate Loci with Alopecia Areata Susceptibility in Jordanian Patients.Medicina (Kaunas, Lithuania) · 2025Article
- Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.Frontiers in medicine · 2025Article
- Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe.Dermatology and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlopecia areata (AA) is an autoimmune disease characterized by the development of non-scarring alopecia. The prevalence is not well known, and estimates vary considerably with no recent estimates in the United States (US). The objective of this study was to define the current AA point prevalence estimate among the general population in the US overall and by severity. PATIENTS AND
methodsWe administered an online, cross-sectional survey to a representative sample of the US population. Participants self-screening as positive for AA using the Alopecia Assessment Tool (ALTO) also completed the Severity of Alopecia Tool (SALT) to measure the severity of disease as a percent of scalp hair loss. Self-reported AA participants were invited to upload photographs for adjudication of AA by 3 clinicians.
resultsThe average age of participants was 43 years. Approximately half of the participants (49.2%) were male, and the majority were white (77.1%) and not of Hispanic origin (93.2%). Among the 511 self-reported AA participants, 104 (20.4%) uploaded photographs for clinician evaluation. Clinician-adjudicated point prevalence of AA was 0.21% (95% CI: 0.17%, 0.25%) overall, 0.12% (95% CI: 0.09%, 0.15%) for "mild" disease (≤50% SALT score), and 0.09% (95% CI: 0.06%, 0.11%) for "moderate to severe" disease (>50% SALT score) with 0.04% (95% CI: 0.02%, 0.06%) for the alopecia totalis/alopecia universalis (100% SALT score) "moderate to severe" subgroup. The average SALT score was 44.4% overall, 8.8% for "mild", and 93.4% for "moderate to severe".
conclusionThis study suggests that the current AA prevalence in the US is similar to the upper estimates from the 1970s at approximately 0.21% (700,000 persons) with the current prevalence of "moderate to severe" disease at approximately 0.09% (300,000 persons). Given this prevalence and the substantial impact of AA on quality of life, the burden of AA within the US is considerable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.